3933 related articles for article (PubMed ID: 28482906)
21. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
Wang YS; Ma LN; Sun JX; Liu N; Wang H
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
Peng DX; Luo M; Qiu LW; He YL; Wang XF
Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
[TBL] [Abstract][Full Text] [Related]
23. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
24. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
26. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
[TBL] [Abstract][Full Text] [Related]
27. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer.
Wen N; Wang Y; Wen L; Zhao SH; Ai ZH; Wang Y; Wu B; Lu HX; Yang H; Liu WC; Li Y
J Transl Med; 2014 May; 12():134. PubMed ID: 24885308
[TBL] [Abstract][Full Text] [Related]
29. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
30. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
32. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
Xie X; Yang M; Ding Y; Yu L; Chen J
Oncol Rep; 2017 Dec; 38(6):3297-3308. PubMed ID: 29039544
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
34. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.
Pinciroli P; Alberti C; Sensi M; Canevari S; Tomassetti A
BMC Genomics; 2013 Jul; 14():508. PubMed ID: 23889749
[TBL] [Abstract][Full Text] [Related]
35. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
37. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
[TBL] [Abstract][Full Text] [Related]
38. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
39. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
40. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
